Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma

Metastatic Melanoma Clinical Trial

— TIL  

Official title:

Randomized Phase III Study Comparing a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 to Standard Ipilimumab Treatment in Metastatic Melanoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02278887
• Other study ID #: M14TIL
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: September 23, 2014
• Est. completion date: June 2027

Study information

• Verified date: November 2023
• Source: The Netherlands Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this randomized controlled phase III study the investigators will evaluate whether TIL infusion preceded by non-myeloablative chemotherapy and followed by high dose bolus interleukin-2 can result in an improved progression free survival when randomly compared to ipilimumab in 168 stage IV melanoma patients. A health technology assessment (HTA) will be performed to evaluate the impact of the TIL treatment on patients and organizational processes and cost-effectivity.

Description:

In this randomized controlled phase III study the investigators will evaluate whether TIL infusion preceded by non-myeloablative chemotherapy and followed by high dose bolus interleukin-2 can result in an improved progression free survival when randomly compared to ipilimumab in 168 stage IV melanoma patients. A health technology assessment (HTA) will be performed to evaluate the impact of the TIL treatment on patients and organizational processes and cost-effectivity. This will be done via questionnaires at baseline, just after treatment and during follow-up. Also healthcare providers will be interviewed after 6 months after starting the trial.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 168
• Est. completion date: June 2027
• Est. primary completion date: September 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Histologically confirmed unresectable AJCC stage III or stage IV melanoma

• Patients must have metastatic melanoma with a resectable metastatic lesion(s) of sufficient size (= 2-3 cm in total) and must be willing to undergo such a resection for experimental purposes.

• Patients should have received maximum one line of systemic therapy (except for ipilimumab) for unresectable or metastatic melanoma.[

• Patients must be = 18 years and = 75 years of age and must have measurable disease by CT or MRI per RECIST 1.1 criteria (in addition to the resected lesion).

• Patients must have a clinical performance status of ECOG 0 or 1.

• Patients of both genders must be willing to practice a highly effective method of birth control during treatment and for four months after receiving the preparative regimen.

• Patients must be able to understand and sign the Informed Consent document.

Exclusion Criteria:

• Life expectancy of less than three months.

• Patients with metastatic ocular/ mucosal or other non-cutaneous melanoma.

• Adjuvant treatment with ipilimumab within 6 months prior to randomization.

• Requirement for immunosuppressive doses of systemic corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive drugs within the last 3 weeks prior to randomization.

• Patients who have a more than two CNS metastases.

• Patients who have any CNS lesion that is symptomatic, greater than 1 cm in diameter or show significant surrounding edema on MRI scan will not be eligible until they have been treated and demonstrated no clinical or radiologic CNS progression for at least 2 months.

• All patients' toxicities due to prior non-systemic treatment must have recovered to a grade 1 or less. Patients may have undergone minor surgical procedures or focal palliative radiotherapy (to non-target lesions) within the past 4 weeks, as long as all toxicities have recovered to grade 1 or less.

• Women who are pregnant or breastfeeding, because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.

• Any active systemic infections, coagulation disorders or other active major medical illnesses.

• Any autoimmune disease

Related Conditions & MeSH terms

• Melanoma
• Metastatic Melanoma

Intervention

Procedure:
• Translational research
Before during and at progression/regression biopsies and blood will be taken for translational research

Drug:
• Cyclophosphamide
The patient receives 2 days cyclophosphamide via IV to deplete T-cells.
• Fludarabine
The patient receives 5 days fludarabine via IV to deplete T-cells.
• Interleukin-2
After infusion of the TIL, the patient receives IL-2 to keep the TIL active.
• Ipilimumab infusion
In arm A patients will be treated with 4 infusion of ipilimumab

Locations

Country	Name	City	State
Denmark	CCIT Department of Oncology and Haematology Herlev Hospital	Copenhagen
Netherlands	Netherlands Cancer Institute	Amsterdam	NH

Sponsors (2)

Lead Sponsor	Collaborator
The Netherlands Cancer Institute	Copenhagen University Hospital at Herlev

Countries where clinical trial is conducted

Denmark,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Safety	Adverse events will be assessed during treatment and follow-up	3 years
Primary	Progression free survival	Progression free survival according to RECIST 1.1	3 years
Secondary	Immune related progression free survival		3 years